Apple Watch 11 — here's the 5 biggest rumored upgrades
We only have a month left to go until Apple's expected to launch the Apple Watch Series 11 at its September event. Thanks to plenty of Apple Watch Series 11 leaks, we already have a pretty good idea of what to expect from the next premium Apple timepiece. While the watch's design itself isn't expected to change much, the recently announced watchOS 26 promises to overhaul its look and feel as well as introduce several new features.
Don't expect any new sensors, as Apple says its long-awaited non-invasive blood glucose monitoring is still "many years away." Though we can be sure it'll show off some handy new features powered by Apple Intelligence. We'll have to see whether that'll be enough for Apple's lineup to make the cut for our best smartwatches ranking.
With the clock winding down before its big reveal, we're rounding up all the biggest Apple Watch Series 11 upgrades that have been rumored so far.
Updated S11 and modem chips
Just because the Apple Watch Series 11 isn't getting a design overhaul doesn't mean there aren't a few hardware upgrades in store. Apple upgrades its processor with every smartwatch release, so we expect to see an updated S11 chip, which could improve performance and battery life.
Apple's latest smartwatches could get a serious new connectivity improvement too. The Apple Watch Series 11 lineup is rumored to pack new modems from MediaTek with 5G RedCap support, which could finally let Apple's wearables ditch LTE connectivity for 5G. Satellite connectivity could be coming for the rugged Watch Ultra 3 as well, according to Bloomberg's Mark Gurman.
New WatchOS 26 features
As we said, easily the biggest upgrade coming to the Apple Watch Series 11 is the new watchOS 26. The latest software adds plenty of new features to play with, like Wrist Flick gesture controls, which make dismissing notifications and alerts as easy as, well, a flick of the wrist. It seems so simple and intuitive, I'm surprised it took Apple over 10 years to implement it.
Then there's the Workout Buddy, which is sure to prove popular. Apple's new personalized exercise coach helps you make the most of your workouts by providing tips, analysis, and motivation. It even sounds like a personal trainer is right there with you, cheering you on, because it uses an AI model trained on voice data from real Apple Fitness Plus trainers.
WatchOS 26 also brings a long-requested feature to Apple smartwatches: Notes app support. All of your existing notes automatically sync to the app for easy viewing, but unfortunately, "viewing" is all you can do. You still won't be able to edit notes with your Apple Watch, though you can start a new one using the screen's tiny keyboard or audio dictation.
Those curious can download the watchOS 26 beta right now for a test run. While you're at it, be sure to check out our full round-up of watchOS 26 features we can't wait to try.
Sleep score
At long last, Apple seems to be developing a sleep score feature for Apple Watch. Code found in iOS 26 suggests the Watch Series 11 could algorithmically monitor and rank the user's time spent and quality of sleep.
It's a feature already found on many of the best smartwatches, but it'll be interesting to see Apple's spin on it. Especially given that many of Apple's existing health features, such as sleep apnea detection, are either backed by clinical research or cleared by the FDA. It's possible Apple's sleep score will take multiple health metrics into account, similar to what we saw with the Vitals option introduced with watchOS 11.
Blood pressure tracking
The Watch Ultra 3 is said to be Apple's first wearable to support blood pressure monitoring. While it's not the first smartwatch on the market to do so (Samsung's Galaxy Watch 3 can also track your blood pressure), Apple's implementing this new feature in a pretty ingenious way.
Rather than providing an exact figure on diastolic or systolic measurements like you get with an on-the-arm cuff, this will work more like the sleep apnea detector to let the wearer know when their blood pressure starts creeping up.
Once the user is notified about hypertension, the watch can give that information to a medical professional for additional testing. Just like other Apple Watch features that provide an early warning system for potential health concerns.
Liquid glass interface
Finally, the Watch Series 11 is set to bring iOS 26's biggest (and most divisive) selling point to Apple's line of wearables: liquid glass. Like the name would suggest, the liquid glass interface gives apps a translucent finish devoid of color, letting on-screen elements behind it bleed through as if seen through glass. You can already test out how liquid glass looks with the watchOS 26 beta.
Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
More from Tom's Guide
If you're using your Apple Watch to track sleep, here's 3 features you should be using
I biked 11 miles with the Apple Watch 10 vs Garmin Forerunner 570 — here's the winner
Google Pixel Watch 4 leak reveals a stunning design — and every color
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
HeartBeam Reports Second Quarter 2025 Results
Executing on Commercial Readiness Plans in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software Engaged in Ongoing Productive Discussions with FDA Related to the 510(k) Application Increased Business Development Resources to Match Inbound Interest from Industry Partners Management to Host Webcast and Conference Call Today at 4:30 p.m. ET SANTA CLARA, Calif., August 13, 2025--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the second quarter ended June 30, 2025. Second Quarter & Subsequent 2025 Operational Highlights The Company continues to make significant progress towards commercial readiness, along with key clinical and regulatory achievements on the HeartBeam System. 12-Lead ECG Synthesis Software FDA Submission: Productive discussions are ongoing with FDA on 510(k) submission for the 12-lead ECG synthesis software in arrhythmia assessment. Timeline for FDA clearance remains firmly on track, expected by the end of the year. Presented results from pivotal VALID-ECG study in April, demonstrating that HeartBeam successfully met the clinical endpoints, with a 93.4% overall diagnostic agreement indicating that the synthesized 12-lead ECG can support diagnosis of arrhythmias in a manner consistent with standard 12-lead ECGs. Commercial Readiness Plans: Anticipate initiating commercialization upon receiving 510(k) clearance for the 12-lead ECG synthesis software. Executing on commercial readiness plans, including finalizing cardiology reader service to provide on-demand cardiologist reviews of synthesized 12-lead ECGs and triage patients. Established infrastructure for customer service, contract manufacturing, and logistics and fulfillment efforts. Proximity to FDA Clearance and commercialization is intensifying business development activity. Expanded the business development team with recognized industry expert. Other Highlights: Abstract on HeartBeam AI algorithm accepted for presentation at HRX Live 2025 in September. New international patent issued, increasing the Company's moat around its core technology; total of 21 issued patents worldwide. Received two additional industry recognitions, adding to the growing list of recent industry recognitions: Awarded the Innovation Award in Remote Cardiac Diagnostics as part of the 2025 Medical Device Network Excellence Awards for its groundbreaking ECG technology. Named finalist in 2025 Octane High Tech Awards, which recognizes innovators, entrepreneurs and technology leaders with a presence in Orange County. Cash, cash equivalents, and short-term investments totaled $5.1 million as of June 30, 2025, with net cash used in operating activities of $3.4 million for the three months ended June 30, 2025, resulting in a 23% decrease quarter-over-quarter. Management Commentary "In the quarter, we continued to engage in positive and productive discussions with the FDA on the 12-lead ECG synthesis software submission for arrhythmia assessment and we continue to anticipate clearance by the end of the year. As we have discussed, that clearance, together with our foundational clearance, will form the basis for our commercial launch," said Robert Eno, Chief Executive Officer, HeartBeam. "We continue to make significant progress with commercial readiness plans, which is positioning us for a successful launch following 510(k) clearance of our 12-lead synthesis software. "Additionally, we are seeing a marked increase in interest from industry partners as we get closer to our 12-lead ECG synthesis clearance and commercialization. We believe these players understand that HeartBeam's technology is transformative and is an ideal platform in the form of a cable free ECG that produces a synthesized 12-lead ECG output. There are multiple ways for partners to get involved in the HeartBeam ecosystem, including data and AI, companion products and services, and complementary diagnostics and treatments. "Our vision for the near future is to bring additional capabilities of a synthesized 12-lead ECG into patients' hands outside of the healthcare setting. One of the most important trends in medicine today is the movement of medical grade devices from the hospital and clinic to the patient. Accurate, connected, medical grade technologies have been shown to expand access, reduce healthcare costs and enable personalized medicine. Within cardiac diseases there is a major gap and a huge opportunity. Cardiac diseases are the leading cause of death worldwide and most cardiac events, whether arrhythmias or ischemia, happen outside of the healthcare setting. Diagnosing these events is crucial for patients and for the healthcare system and we believe that as we implement our vision, our technology will be well positioned to accomplish this," concluded Eno. Second Quarter 2025 Financial Results Research and development expenses for the second quarter of 2025 were $3.3 million, compared to $2.8 million for the second quarter of 2024. General and administrative expenses for the second quarter of 2025 were $1.7 million compared to $2.2 million for the second quarter of 2024. Net loss for the second quarter of 2025 was $5.0 million, compared to a net loss of $5.0 million for the second quarter of 2024. Net cash used in operating activities was $7.9 million for the six months ended June 30, 2025, as compared to $7.0 million for the six months ended June 30, 2024. Cash, cash equivalents, and short-term investments totaled $5.1 million as of June 30, 2025, with net cash used in operating activities of $3.4 million during the period. Second Quarter 2025 Results Conference Call HeartBeam CEO Robert Eno and CFO Tim Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company's website here. To access the call, please use the following information: Date: Wednesday, August 13, 2025 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Dial-in: 1-844-826-3035 International Dial-in: 1-412-317-5195 Conference Code: 10201583 Webcast: HeartBeam Second Quarter 2025 Earnings Conference Call A telephone replay will be available approximately three hours after the call and will run through November 13, 2025, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 10201583. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company's investor relations section here. About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is under FDA review. The Company holds over 20 issued patents related to technology enablement. For additional information, visit Forward-Looking Statements All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Cleared Indications for Use The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead (in three-directions) electrocardiogram (ECG) acquired from 5 electrodes. The device is intended to be used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional. For full safety information, see the full Instructions for Use or Clinician Portal Manual. HEARTBEAM, INC. Condensed Balance Sheets (Unaudited) (In thousands, except share data) June 30, 2025 December 31, 2024 Assets Current Assets: Cash and cash equivalents $ 3,256 $ 2,377 Short-term investments (Note 3) 1,797 — Prepaid expenses and other current assets 308 393 Total Current Assets 5,361 2,770 Property and equipment, net 564 450 Other assets 56 56 Total Assets $ 5,981 $ 3,276 Liabilities and Stockholders' Equity Current Liabilities: Accounts payable (includes related party $0 and $5, respectively) $ 814 $ 531 Accrued expenses (includes related party $5 and $0, respectively) 985 1,091 Total Current Liabilities 1,799 1,622 Total Liabilities 1,799 1,622 Commitments (Note 7) Stockholders' Equity Preferred stock - $0.0001 par value; 10,000,000 authorized; 0 shares outstanding at June 30, 2025 and December 31, 2024 — Common stock - $0.0001 par value 100,000,000 shares authorized; 34,020,340 and 26,960,901 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 4 3 Additional paid in capital 70,909 57,924 Accumulated deficit (66,731 ) (56,273 ) Total Stockholders' Equity 4,182 1,654 Total Liabilities and Stockholders' Equity $ 5,981 $ 3,276 HEARTBEAM, INC. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share data) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Operating Expenses: General and administrative $ 1,711 $ 2,246 $ 3,720 $ 4,602 Research and development 3,326 2,844 6,818 5,272 Total operating expenses 5,037 5,090 10,538 9,874 Loss from operations (5,037 ) (5,090 ) (10,538 ) (9,874 ) Other Income and (Expense) Interest income 63 134 80 312 Total other income 63 134 80 312 Loss before provision for income taxes (4,974 ) (4,956 ) (10,458 ) (9,562 ) Income tax provision — — — — Net Loss $ (4,974 ) $ (4,956 ) $ (10,458 ) $ (9,562 ) Net loss per share, basic and diluted $ (0.15 ) $ (0.19 ) $ (0.32 ) $ (0.36 ) Weighted average common shares outstanding, basic and diluted 33,834,950 26,566,832 32,184,025 26,538,863 HEARTBEAM, INC. Condensed Statements of Cash Flows (Unaudited) (In thousands) Six months ended June 30, 2025 2024 Cash Flows From Operating Activities Net loss $ (10,458 ) $ (9,562 ) Adjustments to reconcile net loss to net cash used in operating activities Depreciation 15 — Stock based compensation expense 2,286 2,247 Changes in operating assets and liabilities: Prepaid expenses and other current assets 85 92 Accounts payable and accrued expenses 150 210 Net cash used in operating activities (7,922 ) (7,013 ) Cash Flows From Investing Activities Purchase of property and equipment (102 ) (98 ) Purchase of short-term investments (3,760 ) — Maturities of short-term investments 1,963 — Net cash used in investing activities (1,899 ) (98 ) Cash Flows From Financing Activities Proceeds from sale of equity, net of issuance costs 10,250 — Proceeds from sale of equity under ATM, net of issuance costs 450 76 Proceeds from exercise of stock options — 8 Net cash provided by financing activities 10,700 84 Net increase (decrease) in cash and restricted cash 879 (7,027 ) Cash, cash equivalents and restricted cash – Beginning of period 2,433 16,239 Cash, cash equivalents and restricted cash – Ending of period $ 3,312 $ 9,212 Reconciliation of cash, cash equivalents and restricted cash: Cash and cash equivalents $ 3,256 $ 9,157 Restricted cash (included in other assets) 56 55 Total cash, cash equivalents and restricted cash $ 3,312 $ 9,212 Supplemental Disclosures of Cash Flow Information: Purchase of property and equipment in accounts payable $ 27 $ 16 Taxes paid $ — $ — View source version on Contacts Investor Relations Contact: Chris Tyson Executive Vice PresidentMZ North AmericaDirect: 949-491-8235BEAT@ Media Contact: media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
U.S. Reportedly Uses Trackers In AI Chip Shipments
Nvidia (NASDAQ:NVDA) is back in the spotlight after a Reuters report said U.S. authorities have secretly placed location trackers in select AI server shipments to catch illegal diversions to China. The devices apply only to shipments under investigation and are meant to help build cases against people and companies that break export rules. People in the supply chain say they have seen trackers on some Dell Technologies (NYSE:DELL) and Super Micro (NASDAQ:SMCI) servers carrying Nvidia and AMD (NASDAQ:AMD) chips, often tucked into packaging and sometimes inside the servers. Warning! GuruFocus has detected 5 Warning Signs with NVDA. Nvidia declined to comment. Super Micro said it does not disclose security practices. Dell said it is not aware of a government initiative to place trackers in its shipments. Authorities can use administrative approval or a judge's warrant, and companies may consent if they are not targets. How often this happens is unclear. Two China based resellers said they now check diverted shipments for trackers. In a 2024 example, a Dell server shipment with Nvidia chips reportedly had large devices about the size of a smartphone and smaller discreet trackers, and a DOJ affidavit described instructions to inspect Quanta H200 servers. covert tracking raises the enforcement bar and could slow gray market tighter export policing and watch for follow on cases and routing changes. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Reliving An Oldtime Rangers Radio Broadcast
Because of advances in technology and technique, Rangers fans have been able to enjoy games on MSG Networks' telecasts as if you're virtually at the games.
